CLOs on the Move

Nomad Health

www.nomadhealth.com

 
Nomad Health is the first digital marketplace for healthcare jobs, efficiently connecting quality clinicians with rewarding career opportunities and taking the busywork out of finding clinical work. We are a well-funded Series C startup backed by First Round Capital, RRE Ventures, .406 Ventures, Polaris Partners, Icon Ventures, and Kevin Ryan (founder of MongoDB, Zola, Gilt, and DoubleClick). The U.S. healthcare system is experiencing a staffing crisis. Employers spend $20 billion per year recruiting clinicians to provide care for patients around the country. Nomad replaces antiquated staffing agencies with modern technology to efficiently source, qualify, and hire medical talent on demand. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Chris Cheng
General Counsel and Corporate Secretary Profile
Chris Cheng
General Counsel, Corporate Secretary and Profile

Similar Companies

Accelerate Sports

Sports Facility | Whitesboro, NY

Alternate Health

Alternate Health (CSE: AHG, OTCQB: AHGIF) an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Alternate Health`s industry-leading software systems provide the platform for the company`s diverse operations, including blockchain tax collection systems, hemp-derived CBD product distribution, extract manufacturing and patient management systems for specialty clinics across North America. Through Alternate Health`s subsidiary, Blaine Labs, the Company is a leader in cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health`s corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders.

Mass AHU

Mass AHU is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Path Mental Health

Path is a healthcare company powered by technology. We`re a teletherapy company that doesn`t compromise on quality — we measure progress and prioritize patient outcomes. Path takes a patient-first approach, where treatment is more accessible, personalized, and effective. With Path, it`s easy to find a high-quality therapist or psychiatric practitioner who meets your unique needs, accepts insurance, and is taking new patients. For providers, Path offers the flexibility of private practice, while also filling caseloads and offering the necessary behind-the-scenes support. Path handles the marketing, credentialing, billing, and admin tasks so providers can focus on what they love: providing care to those in need. With no minimum caseload required and guaranteed payments, Path is a trusted partner for more than 8,000 therapists nationwide and has hundreds of 5-star reviews. Our mission is to make mental healthcare work for everyone. Path is a 100% remote healthtech company and we`re hiring! We have teams who specialize in the areas of Clinical, Finance, Operations, Marketing, Engineering, Product, and more. We`re excited to bring people onto the team who are committed to changing how mental health is treated.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.